Company news

Tenax Therapeutics, Inc. news in 2020

Tenax Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update

November 15, 2020

Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

November 9, 2020

Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation

October 14, 2020

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

October 1, 2020

Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

August 30, 2020

Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

August 16, 2020

Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

July 19, 2020

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

July 5, 2020

Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

June 1, 2020

Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

April 8, 2020

Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

March 11, 2020

Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

February 20, 2020

Decks in 2020